INDIANOLA, Pa., Nov. 22 /PRNewswire/ -- MEDRAD, Inc. introduces the Spectris Solaris(R) EP MR Injection System, an extension of the Spectris Solaris product family with increased battery capacity and a design that enables it to operate with 3T and open scanners, in any proximity to the magnet. The Spectris Solaris EP (Enhanced Performance) also offers an Integrated Continuous Battery Charger (iCBC) option, for high-volume customers who require the flexibility of battery or AC power charge mode.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGO )
The Spectris Solaris EP will be shown at the Annual Meeting of the Radiological Society of North America (RSNA) in Chicago (Booth #1929, South Building). FDA 510 (k) clearance of the product is pending; it is expected to be available globally by the end of first quarter 2005.
Spectris Solaris is the leading MR injection system in the world, with 100 percent customer satisfaction scores for ease of use and overall satisfaction. The enhancement was initiated in response to customer feedback that fewer recharges would enable technologists to focus more on the patient and improve throughput efficiency. “Our field teams conveyed this feedback and the upgrade was put in motion, consistent with our goals of exceptional customer satisfaction and product performance,” says Gary Bucciarelli, senior vice president of the MR Strategic Business Unit. “The product delivers a total customer solution for reliable contrast injection in the MR environment.”
The Spectris Solaris EP retains all of the original Spectris Solaris features including a user-friendly graphical interface for at-a-glance identification of flow rate, volume, scan delay, inject delay and elapsed time. It is supported by MEDRAD’s field sales, service and applications training teams.
MEDRAD, Inc. is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, MEDRAD’s product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and accessory products, and equipment services. Total 2003 revenues were $294 million. MEDRAD is a 2003 recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company’s world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is a U.S. affiliate of Schering AG, Germany . For more information, visit MEDRAD’s website at http://www.medrad.com/ .
Cautionary statement regarding forward-looking statements.
Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and MEDRAD’s plans and objectives to differ materially from those expressed or implied in the forward-looking statements. MEDRAD undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events, circumstances or otherwise.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.comMEDRAD, Inc.
CONTACT: Luanne Radermacher, Corporate Communications, +1-412-767-2400,ext. 3184, or lradermacher@medrad.com , or Dan Dieter, Marketing Services,+1-412-767-2400, ext. 3726, or ddieter@medrad.com , both of MEDRAD, Inc.
Web site: http://www.medrad.com/